THYMOSIN ALPHA-1
Solid research foundation with genuine clinical data, particularly for hepatitis applications. While most peptides rely heavily on animal studies, this one has meaningful human trial evidence.
Immunologists and hepatitis researchers have been the primary investigators, with growing interest from oncology teams studying immune-based cancer therapies.
Since Mar 2024
30 total, 3 human
What is THYMOSIN ALPHA-1?
Originally isolated from the thymus gland, this 28-amino acid peptide has been a fixture in immunology research for decades. Scientists initially discovered it while studying how the thymus trains immune cells, and it's since become one of the more thoroughly investigated immune-modulating compounds. Research teams worldwide have examined its potential in everything from chronic hepatitis to cancer therapy.
The peptide works by acting as a molecular instructor for immune cells, particularly T-cells and dendritic cells that coordinate immune responses. It binds to specific receptors on these cells, triggering a cascade of signals that improves their ability to recognize threats and communicate with other immune components. Think of it as upgrading the software that runs your immune system's command center.
What the Research Shows
The 30-study research base includes substantial human data, though the single randomized controlled trial limits definitive clinical conclusions.
Of 30 total studies (26 human studies, 1 RCT), thymosin alpha-1 demonstrates modest efficacy for hepatitis B and improved outcomes when combined with interferon for hepatitis C, while preclinical evidence suggests potential immunomodulatory mechanisms including macrophage reprogramming and enhanced chemotherapy/oncolytic virus efficacy in cancer models. The limited RCT data and predominance of preclinical studies indicate that clinical applications remain investigational, particularly for oncology indications.
Notable Studies
Ancell CD, Phipps J, Young L · Am J Health Syst Pharm (2001)
RCT · Phase 3 · n=3576-12 months
Cao A, Feng F, Zhou X · J Coll Physicians Surg Pak (2024)
Meta-analysis · n=3 · ,329
Yang YF, Zhao W, Zhong YD et al. · Antiviral Res (2008)
Meta-analysis · n=1996 · months treatment plus 6 months follow-up
Soeroto AY, Suryadinata H, Yanto TA et al. · Inflammopharmacology (2023)
Meta-analysis
Liu K, Kong L, Cui H et al. · Cell Rep Med (2024)
Animal
Reported Benefits
Combinations & Interactions
Regulatory Status
Last verified: Feb 2026
Related Peptides
This information is for research purposes only and does not constitute medical advice. Always consult a licensed physician before using any peptides.